嘉和生物拟根据购回授权于市场上购回股份

Core Viewpoint - The company plans to repurchase its shares in the open market based on the general authorization granted by shareholders at the annual general meeting scheduled for June 26, 2025 [1] Group 1 - The repurchased shares will be used in a manner deemed beneficial for the company's operations [1] - The board believes that the share repurchase aligns with the overall interests of the company and its shareholders [1]